Introduction
WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is a rare combined primary immunodeficiency disease caused by gain-of-function autosomal dominant mutations in CXCR4, a G protein-coupled receptor for the chemokine CXCL12 (1, 2) . Among other functions, CXCR4 normally promotes BM homing and retention of neutrophils and hematopoietic stem cells (HSCs) , as well as HSC quiescence (3) (4) (5) (6) . The WHIM mutation increases BM retention of neutrophils, causing neutropenia, a hematologic picture referred to as myelokathexis (7) (8) (9) . G-CSF, which is commonly used to treat neutropenia in patients with WHIM, selectively increases the neutrophil count in part by inducing degradation of CXCL12, thereby reducing CXCR4 signaling (2, 10) .
Discovery of CXCR4 as the disease gene in WHIM syndrome has provided a precise target for development of novel therapeutic strategies. Regarding drug development, 2 specific CXCR4 antagonists, plerixafor (Mozobil, Sanofi, AMD3100) and X4P-001 (AMD11070), are currently in clinical trials (11) (12) (13) . With regard to cure, several patients have been cured by allogeneic BM transplantation (14, 15) , and one patient has been cured by spontaneous deletion of the WHIM allele in a single HSC by chromothripsis (chromosome shattering). Remarkably, the chromothriptic HSC in this patient acquired a selective growth advantage leading to approximately 100% chimerism with CXCR4-haploinsufficient (CXCR4
+/o
) myeloid cells (16) . The genetic mechanism responsible for myeloid repopulation remains undefined, in large part because 163 other genes were also deleted by the chromothriptic event. Nevertheless, a potential contribution from CXCR4 haploinsufficiency alone is supported by a mouse model of the patient in which the haploinsufficient (Cxcr4 ) genotypes after competitive BM transplantation in lethally irradiated congenic recipient mice (16) . Importantly, cure of these patients demonstrates that the hematologic phenotypes and infection susceptibility in WHIM syndrome are driven by expression of the WHIM allele in hematopoietic cells, which suggests that both correcting and deleting the disease allele in patient HSCs are rational curative gene therapy strategies. The Cxcr4
+/+ competitive BM transplantation experiments in lethally irradiated mice suggested that disease allele deletion may actually be superior to disease allele correction as a gene therapy strategy because of the potential for enhanced engraftment of Cxcr4 +/o HSCs. Here we test this hypothesis directly in mouse models of gene therapy for WHIM syndrome. Cxcr4-haploinsufficient bone marrow transplantation corrects leukopenia in an unconditioned WHIM syndrome model Figure 2 ), and independent of the CD45 genetic background of the donor mice (Supplemental Figure 3) .
Results and Discussion
For the Cxcr4
+/w competition, the absolute numbers of Cxcr4 +/o donor-derived mature leukocytes rapidly increased to the average value for each subset for Cxcr4 +/+ mice, whereas the absolute numbers of Cxcr4 +/w donor-derived mature leukocytes remained below the average value for Cxcr4 +/w mice ( Figure 1C ). In contrast, when each donor BM was transplanted independently into lethally irradiated Cxcr4 +/+ recipients, the steady state absolute numbers of donor-derived peripheral blood leukocytes in the recipients consistently tracked the average values for the corresponding subset in donor mice (Supplemental Figure 4) blood reconstitution by mature donor-derived leukocytes in the same animals ( Figure 2B ). This provides evidence for a posthoming BM engraftment advantage conferred by Cxcr4 haploinsufficiency to transplanted HSCs. CXCR4 is also known to mediate retention of HSCs and neutrophils in BM (4, 18) . Thus, biased BM retention of mature Cxcr4 +/w leukocytes must be considered as a potential explanation for the blood results. We found no evidence for this in the Cxcr4
+/+ competition ( Figure 2C ). However, in the Cxcr4
+/w competition, we observed significantly higher frequencies of mature Cxcr4 +/w leukocytes, especially B and T cells, in BM than in blood, and conversely, higher frequencies of Cxcr4 +/o mature leukocytes in blood than in BM ( Figure 2C ). Thus, biased BM retention of certain mature leukocytes in this competi- (Figure 2A ). However, this ratio was inverted when BM was analyzed 465 days after competitive transplantation, aligning with the Cxcr4 genotype rank order for ; MPP, multipotent progenitors. *P < 0.05; **P < 0.01; ***P < 0.005; **** P < 0.001; NS, not significant, Student's t test. jci.org
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Although enhanced HSC proliferation has been reported to possibly result in HSC exhaustion and depletion, and maintenance of HSCs in quiescence has been reported to favor long-term hematopoiesis (19-21), we did not observe any evidence of BM failure as late as 465 days after competitive transplantation of Cxcr4 +/o HSCs ( Figure 1B, Figure 2C , and Supplemental Figure 6 ). Furthermore, in a formal aging study we found no difference in survival and health of Cxcr4 +/o mice compared with Cxcr4 +/+ littermates ( Figure 2E ).
Leukopenia can be corrected in WHIM mice by Cxcr4
+/o BM transplantation without recipient conditioning. We next tested whether Cxcr4 genotype also affects engraftment after competitive BM transplantation in unconditioned congenic recipient mice. Overtion may contribute to the net hematopoietic reconstitution activity rank order conferred by Cxcr4 genotype to transplanted BM.
CXCR4 is also known to inhibit cell proliferation (5). Consistent with this, in our previous report we found that Cxcr4
HSCs were hyperproliferative compared with Cxcr4 +/+ HSCs (16). Likewise, here we found that BrdU + cell frequency was approximately 20% greater for Cxcr4 +/o HSCs than for Cxcr4 +/w HSCs 20 hours after BrdU injection 7 days after competitive transplantation ( Figure 2D and Supplemental Figure 5) . Thus, the superiority of Cxcr4 +/o BM for reconstituting peripheral blood leukocytes after competitive transplantation in lethally irradiated mice may involve an early HSC proliferative advantage. Figure  3A) . Overall, for each BM donor, myeloid cells reconstituted the best and CD3 + cells the least well.
all, the Cxcr4 genotype rank order for donor leukocyte reconstitution in peripheral blood was the same as when lethally irradiated Cxcr4
+/+ mice were tested as the recipients: Cxcr4
, which is greater than Cxcr4
, which is greater than Cxcr4 +/w (compare Figure 1A and Figure 3A ). In the Cxcr4
+/w competition, the frequency of differentially marked Cxcr4 +/w donor-derived cells was only 1%-4%, whereas the frequencies of donor-derived Cxcr4 +/o myeloid and B cells reached a plateau of 20%-40% by 100 days after transplantation that remained stable out to 315 days when the experiment was arbitrarily terminated. Cxcr4 +/+ BM ) from each of the indicated donors were transplanted separately into unconditioned Cxcr4 +/w mice. Experiment design is shown on the upper left. Mice were euthanized on day 348 after transplantation for mature leukocyte subset analysis in blood and BM, and HSC and HPC analysis in BM. For both A and B, data are the percentage (mean ± SEM) of total cells contributed by the indicated donor (Cxcr4 genotype abbreviated as +/o or +/w) for each indicated HSC/HPC subset in BM and mature leukocyte subset in BM and blood (n = 5 mice per data point). **P < 0.01; ***P < 0.005; ****P < 0.001, Student's t test. NS, not significant. jci.org Volume 128 Number 8 August 2018
The quite different BM results in the 2 transplantation models tested here suggest that the increased proliferative potential of Cxcr4 +/o HSCs over Cxcr4 +/w HSCs may only become manifest when stem cell niches are present in great excess over available donor HSCs or when it is needed for an immune response. The number of HSCs in BM is thought to be limited by the total number of specific niches available (5, 23) . We speculate that in the lethally irradiated recipient model, the proliferative advantage of Cxcr4 +/o HSCs is not limited by niche availability. In contrast, in unconditioned WHIM mice, most niches are already occupied. Therefore, HSC engraftment is limited regardless of the Cxcr4 genotype. In unconditioned Cxcr4 +/w recipients, leukopenia may stimulate production of mature leukocytes from both Cxcr4 +/w and Cxcr4 +/o HSCs. However, differential HSC proliferation and mature myeloid cell egress from BM may provide the selective mechanism for restoring the peripheral myeloid cell counts to normal with donor-derived Cxcr4 +/o but not Cxcr4 +/w cells. A limitation of this interpretation is that it is difficult to directly evaluate donor-derived HSC proliferation in vivo in unconditioned recipients due to the paucity of these cells in BM and the slow time course of engraftment.
Importantly, we found that reconstitution of unconditioned WHIM mice with Cxcr4 +/o leukocytes was durable after BM transplantation, and that survival in mice with a single copy of Cxcr4 in their hematopoietic cells is normal. Although our results are not consistent with CXCR4 haploinsufficiency being the sole genetic explanation for the patient with WHIM who was cured by chromothripsis (16), they do suggest that CXCR4 haploinsufficiency may have contributed. The patient is also haploinsufficient for 163 other genes, so many other possible genetic mechanisms must be considered. Nevertheless, our results support further development of a cure strategy for WHIM syndrome focused on syngeneic transplantation of patient HSCs in which the WHIM allele has been deleted by gene editing and patient conditioning is limited or even unnecessary.
Methods
Detailed methods are described in the Supplemental Methods online.
Statistics. All data are presented as mean ± SEM. The 2-tailed Student's t test was used for single comparisons and 2-way ANOVA was used for multiple comparisons. P < 0.05 was considered significant.
Study approval. All animal experiments were approved by the IACUC of the National Institute of Allergy and Infectious Diseases.
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Since chimerism in an unconditioned congenic transplantation system is donor BM cell dose-dependent (22), we tested different doses and found that transplantation of 5 × 10 7 Cxcr4 +/o BM cells alone into unconditioned Cxcr4 +/w recipients ( Figure 3B ), which established 60%-70% donor chimerism at steady state for total leukocytes, myeloid cells, and B cells (Figure 3B ), restored the absolute myeloid cell counts to the normal range for Cxcr4 +/+ mice ( Figure 3B ). In contrast, transplantation of 5 × 10 7 Cxcr4
+/w BM cells alone resulted in no greater than 15% Cxcr4 +/w donorderived CD45 + cells in peripheral blood ( Figure 3B ), and did not significantly increase the absolute cell number ( Figure 3B) Figure 3A) , the frequencies of mature Cxcr4 +/w donorderived leukocytes were very low and similar for each subset in BM and peripheral blood ( Figure 4A ). The BM frequencies of Cxcr4 +/w donor-derived HSCs and HPCs were also very low ( Figure 4A ). In contrast, the frequencies of mature Cxcr4 +/o donor-derived leukocytes were much higher in peripheral blood for each subset than in BM ( Figure 4A) . Surprisingly, the frequencies of Cxcr4 +/o donorderived HSCs and HPCs in BM were also low and similar to the frequencies of Cxcr4 +/w donor-derived HSCs and HPCs in BM (Figure 4A) Figure 3B ), and were analyzed 348 days after transplantation ( Figure 4B) 
